Biopharma company XYRA and FDA have concluded a series of Phase II meetings on managing key studies for potential atrial fibrillation therapy, budiodarone.
XYRA has announced that it has reached an agreement with FDA on the key studies that will form the basis of approval and labeling of orally administered budiodarone for the long-term management of symptomatic non-permanent atrial fibrillation (AFib) following a series of Phase II meetings, according to a company press release.1
AFib, the most common type of arrythmia, is a type of irregular heartbeat that can lead to cardiac events, such as stroke and blood clots, if not treated. The CDC predicts that by 2030, approximately 12.1 million people in the United States will have developed the condition. Further, in 2019, AFib was mentioned on 183,321 death certificates in the United States was listed as the underlying cause of death for 26,535 of those cases.2
According to the press release, the evidence from outcomes studies suggests patients with symptomatic non-permanent AFib, whether paroxysmal (PAF) or persistent, characterized by long episodes of atrial fibrillation (LEAF) lasting longer than 5.5 hours are at highest risk for stroke, heart failure and progression to permanent AFib. FDA has agreed that reducing LEAF could reduce progression to permanent AFib, recently approving a number of wearable AFib monitoring devices.
"Budiodarone is a potentially best-in-class mixed ion channel blocker with features that are designed to enhance safety and efficacy in the treatment of symptomatic non-permanent AFib.We wish to thank the Agency (FDA) for a timely and successful series of EoP2 meetings at which we obtained clear, specific, and useful guidance on the pathway to approval. Integrating FDA approved and validated wearable AFib monitoring devices into the development will allow us to identify eligible subjects and ensure they are then established on the lowest effective approved dose," said Peter Milner MD, FACC, managing member, XYRA in the press release. "We look forward to collaborating with the Agency to demonstrate budiodarone is both safe and effective for the management of symptomatic non-permanent AFib. This is a sizable and growing population with an unmet need and includes subjects with persistent AFib that can be cardioverted, and those with PAF at high risk because of LEAF that is refractory to other therapies."
Of the two key studies XYRA and FDA agreed upon, the first is an open label, long term dose titration study of the 4 doses of budiodarone that were effective in Phase II. Dosing will be guided by the use of an FDA approved wearable device to monitor safety and effectiveness in the Phase III trial. The second is a 6 month double blind randomized controlled trial of the 4 fixed active doses of budiodarone versus placebo in 500 subjects with symptomatic non-permanent AF and LEAF lasting longer than 5.5 hours.
Zerlasiran Achieves Significant Sustained Reduction in Lipoprotein(a) Levels with Infrequent Dosing
November 20th 2024Zerlasiran, a novel siRNA therapy, demonstrated over 80% sustained reductions in lipoprotein(a) levels with infrequent dosing in the Phase II ALPACAR-360 trial, highlighting its potential as a safe and effective treatment for patients at high risk of cardiovascular disease.
Tirzepatide Reduces Heart Failure Risk, Improves Physical Function in HFpEF Patients
November 18th 2024The Phase III SUMMIT trial showed that tirzepatide significantly reduces the risk of worsening heart failure events or death from cardiovascular causes, enhances physical function, and leads to weight loss and reduced inflammation in patients with heart failure with preserved ejection fraction.
Twice-Yearly Lenacapavir Injections Significantly Reduce HIV Risk, PURPOSE 2 Trial Shows
November 13th 2024Full Phase III PURPOSE 2 trial results suggest that twice-yearly lenacapavir could revolutionize HIV prevention by offering a convenient and effective long-acting option for individuals at risk of infection.